Biogen Inc.
BIIB
$147.37
$3.602.50%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -1.62% | -3.86% | -3.00% | -4.37% | -3.32% |
| Total Other Revenue | -- | -- | -- | -105.17% | -108.16% |
| Total Revenue | -1.62% | -3.86% | -3.00% | -4.37% | -3.32% |
| Cost of Revenue | -12.28% | -9.21% | -0.78% | 8.30% | 11.20% |
| Gross Profit | 2.07% | -2.09% | -3.67% | -7.87% | -7.51% |
| SG&A Expenses | -4.72% | -8.64% | 6.25% | 4.06% | 3.87% |
| Depreciation & Amortization | 60.64% | 69.60% | 40.79% | 17.03% | -2.31% |
| Other Operating Expenses | 16.27% | 25.99% | 19.69% | 36.11% | 3,056.76% |
| Total Operating Expenses | -9.34% | -9.06% | 2.22% | 6.42% | 11.16% |
| Operating Income | 30.97% | 16.08% | -17.67% | -31.25% | -37.64% |
| Income Before Tax | 46.98% | 18.46% | -57.91% | -64.12% | -63.92% |
| Income Tax Expenses | 102.37% | 98.57% | -65.72% | -72.04% | -78.62% |
| Earnings from Continuing Operations | 40.53% | 10.42% | -56.57% | -62.71% | -60.78% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | 366.67% | 242.86% | -333.33% | -100.47% |
| Net Income | 40.57% | 10.49% | -56.52% | -62.74% | -61.89% |
| EBIT | 30.97% | 16.08% | -17.67% | -31.25% | -37.64% |
| EBITDA | 32.03% | 19.17% | -11.70% | -25.49% | -32.79% |
| EPS Basic | 39.70% | 9.71% | -56.80% | -62.75% | -61.76% |
| Normalized Basic EPS | 23.71% | 1.25% | -24.13% | -31.94% | -36.84% |
| EPS Diluted | 40.06% | 9.99% | -56.78% | -62.81% | -61.87% |
| Normalized Diluted EPS | 23.91% | 1.44% | -23.98% | -31.95% | -36.89% |
| Average Basic Shares Outstanding | 0.59% | 0.59% | 0.50% | 0.14% | -0.46% |
| Average Diluted Shares Outstanding | 0.48% | 0.50% | 0.28% | 0.09% | -0.45% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
